Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal

Author： Boyers Dwayne  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.6, 2012-06, pp. : 483-495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eltrombopag: a guide to its use in chronic immune (idiopathic) thrombocytopenic purpura

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 2, 2011-02 ,pp. : 5-8

Adis International

Access to resources Recommend Favorite

Eltrombopag is an effective treatment for patients with chronic idiopathic thrombocytopenic purpura

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Refractory Idiopathic Immune Thrombocytopenic Purpura in Children: Current and Future Treatment Options

By Imbach P.  

Pediatric Drugs, Vol. 5, Iss. 12, 2003-01 ,pp. : 795-801

Adis International

Access to resources Recommend Favorite

Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal

By Rodgers Mark  

PharmacoEconomics, Vol. 28, Iss. 5, 2010-05 ,pp. : 351-362

Adis International

Access to resources Recommend Favorite

Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal

By McKenna Claire  

PharmacoEconomics, Vol. 30, Iss. 1, 2012-01 ,pp. : 35-46

Adis International

Access to resources Recommend Favorite